- Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
- Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
- Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
- Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
- Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
- Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
- Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
- Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
More ▼
Key statistics
On Monday, Repare Therapeutics Inc (RPTX:NSQ) closed at 3.89, 30.54% above the 52 week low of 2.98 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.97 |
---|---|
High | 4.18 |
Low | 3.76 |
Bid | 3.75 |
Offer | 4.33 |
Previous close | 3.90 |
Average volume | 188.51k |
---|---|
Shares outstanding | 42.45m |
Free float | 42.03m |
P/E (TTM) | -- |
Market cap | 156.20m USD |
EPS (TTM) | -1.10 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼